ArticleFrontiers in gastroenterology (Lausanne, Switzerland)2026
Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study.
Bolette Christophersen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.